The Impact of Body Mass Index on the Antibody Titer after Astra Zeneca Vaccination at UTA’45 Vaccine Center

Lukas, Stefanus; Laila Ramatillah, Diana; Aldi, Yufri; Sri Wahyuni, Fatma

doi:10.52711/0974-360x.2023.00441

Cited by 2 publications

(1 citation statement)

References 53 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Vaccination creates an immune system in the body so that it can prevent or reduce the possibility of pathogen infection occurring in the future 9 . There are 2 categories of the antibody titer values: the low antibody (< 110 U/mL) and high antibody (> 110 U/mL) 10 .…”

Section: Introductionmentioning

confidence: 99%

Relationship between antibody titer than the Incidence of Infection After Complete Dose of COVID-19 Astrazeneca Vaccination Based on Sociodemographics

Lukas,

Ramatillah,

Aldi

et al. 2024

J. Drug Delivery Ther.

View full text Add to dashboard Cite

Background: Vaccine is an essential tool to limit the health of the COVID -19 pandemic and one of the vaccines that got permitted to used is AstraZeneca Vaccine. The base of the AstraZeneca is the viral vector vaccine. This vaccine has a more advanced method that uses a modified virus to trigger antibodies to make herd immunity for people. Objective: To found correlation between antibody titer than the incidence of Covid infection after complete dose vaccination base on sociodemographics Method: Observasional prospective Cohort method was use in this study with a convenience sampling design. Inclusion criteria were all Indonesian citizens above 18 years old (n=113) who were vaccinated at UTA 45 Jakarta Vaccine Center with no history of COVID -19 before the vaccination and had filled up the informed consents. Results: there were 43 (38%) respondents infected Covid-19 after vaccinated full dosesConclusion: Base on this study, it was found that there was a correlation between sociodemographics after vaccinated full doses AstraZeneca, gender, age, comorbid, smoking, and drinking than infected Covid -19 (P-value < 0.05)). Keywords: Astrazeneca vaccine, Antibody titer, COVID-19.

show abstract

Section: Introductionmentioning

confidence: 99%

Relationship between antibody titer than the Incidence of Infection After Complete Dose of COVID-19 Astrazeneca Vaccination Based on Sociodemographics

Lukas,

Ramatillah,

Aldi

et al. 2024

J. Drug Delivery Ther.

View full text Add to dashboard Cite

show abstract

Current Insights on Vaccines available for COVID-19 like Flu Symptoms

Singh,

Nimisha,

Singh

et al. 2024

RJPT

View full text Add to dashboard Cite

The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) caused pandemic with a rapid spread and became a major public health issue in the world in year 2020. A potentially lethal illness known as coronavirus disease-2019 was produced by this novel coronavirus member (COVID-19). Combatingthe COVID-19/SARS-CoV2 epidemic, which is endangering the foundation of our civilization, resulting in horrific human casualties, and placing a massive economic burden on the whole world, has presented us with an unparalleled task. The creation of novel testing kits and treatment stoco mbatthe pandemic, including the creation of portable, quicklydeployable, and cost-effective diagnostic testing kits, personal protective equipment, mechanical ventilators, vaccines, and data analysis and modelling tools, has become urgently necessary during this trying time. The vaccination of the populace is acknowledged as a public health priority in the current setting of the epidemic caused by SARS-COV-2. The genomic sequencing for SARS-COV2 was completed fast, in just one month. Since then, vaccination has been the focus of research on a global scale. The pandemic has compelled scientists across the globe to research solutions for treatments as well as vaccines to stop COVID-19. Various researches on SARS-CoV and, to a lesser degree, MERS have provided guidance about immunisation tactics regarding this unique coronavirus. It is explained by the statement that the SARS-CoV-2 shares 79% genetic similarity with SARS-CoV and uses human Angiotensin Converting Enzyme 2 (hACE2) receptor on the host cell. There are several platforms for developing vaccines, including virus-vectored vaccines, m-RNA based vaccines, protein subunit vaccines, m-RNA based nanotherapeutics, intranasal vaccines, recombinant spike protein vaccines, self-amplifying m-RNA vaccines and monoclonal antibodies for passive immunisation that are being evaluated for COVID-19. All these platforms have certain pros and cons. The COVID-19 pandemic is possibly the second most deadly in the last century after the Spanish flu that requires a quick assessment of the various target efficacies in inducing immunity in preventing unplanned immune-potentiation. This article aims to give readers a detailed insight intovaccines that will be successful against the new coronavirus that has ravaged the global economy, human health, and quality of life.

show abstract

The Impact of Body Mass Index on the Antibody Titer after Astra Zeneca Vaccination at UTA’45 Vaccine Center

Cited by 2 publications

References 53 publications

Relationship between antibody titer than the Incidence of Infection After Complete Dose of COVID-19 Astrazeneca Vaccination Based on Sociodemographics

Relationship between antibody titer than the Incidence of Infection After Complete Dose of COVID-19 Astrazeneca Vaccination Based on Sociodemographics

Current Insights on Vaccines available for COVID-19 like Flu Symptoms

Contact Info

Product

Resources

About